S. Sorensen

Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.

D. Weisenburger, J. Armitage, D. Howe, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation.

D. Weisenburger, J. Armitage, P. Bierman, 1989, The American journal of medicine.

The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.

D. Weisenburger, J. Armitage, P. Bierman, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma.

J. Armitage, D. Howe, J. Goldsmith, 1988, Chest.

ChlVPP--an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease.

J. Armitage, J. Vose, D. Howe, 1988, American journal of clinical oncology.

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.

D. Weisenburger, J. Armitage, P. Bierman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.

H. Schmidt, M. Nishimura, J. J. Jensen, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity.

D. Weisenburger, P. Bierman, J. Vose, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.